In Vivo Pharmacodynamic Profiling of Doripenem Against Pseudomonas Aeruginosa by Simulating Human Exposures

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2008 May 7

PMID 18458125

Citations 26

Authors

Aryun Kim

Mary Anne Banevicius

David P Nicolau

Affiliations

Soon will be listed here.

Abstract

Doripenem is a new broad-spectrum carbapenem with activity against a range of gram-negative pathogens, including nonfermenting bacteria such as Pseudomonas aeruginosa. The objective of this study was to evaluate simulated human exposures to doripenem using a neutropenic murine thigh infection model against 24 clinical P. aeruginosa isolates with a wide range of MICs. Dosing regimens in mice were designed to approximate the free time above MIC (fT>MIC) observed with 500 mg doripenem every 8 h given as either a 1-h or 4-h intravenous infusion in humans. Maximal antibacterial killing was associated with doripenem exposures of > or =40% fT>MIC; bacteriostatic effects were noted at approximately 20% fT>MIC. The simulated 1-h infusion provided bactericidal effects for isolates with MICs of < or =2 microg/ml, while variable killing was noted for isolates with MICs of 4 to 8 microg/ml and regrowth for isolates with an MIC of 16 microg/ml. The 4-h infusion regimen displayed similar killing for isolates with MICs of < or =2 microg/ml and enhanced activity for two of the four isolates with an MIC of 4 microg/ml. Given that the 4-h regimen yields negligible fT>MIC for MICs of > or =8 microg/ml, regrowth was generally observed. Simulated doses of 500 mg doripenem every 8 h infused over 1 h demonstrated antibacterial killing for P. aeruginosa isolates with MICs of 0.125 to 8 microg/ml. Exposures of > or =40% fT>MIC resulted in the most pronounced bactericidal effects, while killing was variable for 20 to 30% fT>MIC. Infusing doses over 4 h enhanced efficacy against selected pseudomonal isolates with an MIC of 4 microg/ml.

Citing Articles

Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing.

Reza N, Gerada A, Stott K, Howard A, Sharland M, Hope W Clin Microbiol Rev. 2024; 37(2):e0013923.

PMID: 38436564 PMC: 11324030. DOI: 10.1128/cmr.00139-23.

Carbapenem Combinations for Infections Caused by Carbapenemase-Producing : Experimental In Vitro and In Vivo Analysis.

Herrera-Espejo S, Barrio-Tofino E, Cebrero-Cangueiro T, Lopez-Causape C, Alvarez-Marin R, Cisneros J Antibiotics (Basel). 2022; 11(9).

PMID: 36139991 PMC: 9495166. DOI: 10.3390/antibiotics11091212.

Pharmacodynamic Thresholds for Beta-Lactam Antibiotics: A Story of Mouse Man.

Berry A, Kuti J Front Pharmacol. 2022; 13:833189.

PMID: 35370708 PMC: 8971958. DOI: 10.3389/fphar.2022.833189.

Prolonged Versus Intermittent Infusion of β-Lactam Antibiotics: A Systematic Review and Meta-Regression of Bacterial Killing in Preclinical Infection Models.

Dhaese S, Heffernan A, Liu D, Abdul-Aziz M, Stove V, Tam V Clin Pharmacokinet. 2020; 59(10):1237-1250.

PMID: 32710435 DOI: 10.1007/s40262-020-00919-6.

Population Pharmacokinetic Analysis of Doripenem after Intravenous Infusion in Korean Patients with Acute Infections.

Lee D, Kim Y, Jin K, Kang M, Joo Y, Kim Y Antimicrob Agents Chemother. 2017; 61(5).

PMID: 28223378 PMC: 5404572. DOI: 10.1128/AAC.02185-16.

References

Obritsch M, Fish D, MacLaren R, Jung R . National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob Agents Chemother. 2004; 48(12):4606-10. PMC: 529178. DOI: 10.1128/AAC.48.12.4606-4610.2004. View

Andes D, Craig W . In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob Agents Chemother. 1998; 42(9):2375-9. PMC: 105836. DOI: 10.1128/AAC.42.9.2375. View

Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I . Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med. 2008; 36(4):1089-96. DOI: 10.1097/CCM.0b013e3181691b99. View

Jones R, Huynh H, Biedenbach D . Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Antimicrob Agents Chemother. 2004; 48(8):3136-40. PMC: 478547. DOI: 10.1128/AAC.48.8.3136-3140.2004. View

Streit J, Jones R, Sader H, Fritsche T . Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Int J Antimicrob Agents. 2004; 24(2):111-8. DOI: 10.1016/j.ijantimicag.2003.12.019. View

Tam V, Schilling A, Nikolaou M . Modelling time-kill studies to discern the pharmacodynamics of meropenem. J Antimicrob Chemother. 2005; 55(5):699-706. DOI: 10.1093/jac/dki086. View

Bonomo R, Szabo D . Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis. 2006; 43 Suppl 2:S49-56. DOI: 10.1086/504477. View

Turnidge J . The pharmacodynamics of beta-lactams. Clin Infect Dis. 1998; 27(1):10-22. DOI: 10.1086/514622. View

Talbot G, Bradley J, Edwards Jr J, Gilbert D, Scheld M, Bartlett J . Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis. 2006; 42(5):657-68. DOI: 10.1086/499819. View

10.

Livermore D . Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?. Clin Infect Dis. 2002; 34(5):634-40. DOI: 10.1086/338782. View

11.

Jones R, Huynh H, Biedenbach D, Fritsche T, Sader H . Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J Antimicrob Chemother. 2004; 54(1):144-54. DOI: 10.1093/jac/dkh298. View

12.

Fritsche T, Stilwell M, Jones R . Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin Microbiol Infect. 2005; 11(12):974-84. DOI: 10.1111/j.1469-0691.2005.01271.x. View

13.

Craig W . Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998; 26(1):1-10; quiz 11-2. DOI: 10.1086/516284. View

14.

Sutherland C, Nicolau D . Development of an HPLC method for the determination of doripenem in human and mouse serum. J Chromatogr B Analyt Technol Biomed Life Sci. 2007; 853(1-2):123-6. DOI: 10.1016/j.jchromb.2007.03.004. View

15.

. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004; 32(8):470-85. DOI: 10.1016/S0196655304005425. View

16.

White R, Friedrich L, Burgess D, Warkentin D, Bosso J . Comparative in vitro pharmacodynamics of imipenem and meropenem against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1996; 40(4):904-8. PMC: 163228. DOI: 10.1128/AAC.40.4.904. View

17.

Mattoes H, Kuti J, Drusano G, Nicolau D . Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin Ther. 2004; 26(8):1187-98. DOI: 10.1016/s0149-2918(04)80001-8. View

18.

Drusano G . Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol. 2004; 2(4):289-300. DOI: 10.1038/nrmicro862. View

19.

Hori T, Nakano M, Kimura Y, Murakami K . Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intravenously administered to laboratory animals. In Vivo. 2006; 20(1):91-6. View

20.

Lodise T, Lomaestro B, Drusano G . Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2006; 26(9):1320-32. DOI: 10.1592/phco.26.9.1320. View